AIMAH is a controversial disease in the field of blood tumours, with clinical performance being complex and often involving multiple systems. Early identification and normalisation of the disease are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of AIMAH requires the development of a multi-dimensional treatment plan, which typically includes drug therapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the course of the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of AIMAH. The platform serves the China International Medical Service System, a team of nationally and internationally authoritative experts in the field of blood tumours, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.